Blackstone Therapeutics

Blackstone Therapeutics is a biotechnology company focused on the development of next-generation small molecule therapeutics for inflammatory and autoimmune diseases. The company's primary research centers on modulating the glucocorticoid receptor to achieve potent anti-inflammatory effects while minimizing the systemic side effects typically associated with traditional steroid treatments. By leveraging structural biology and medicinal chemistry, Blackstone Therapeutics aims to create highly selective dissociative glucocorticoid receptor modulators (SEGRMs). The company is currently in the pre-clinical stage, advancing its lead candidates toward IND-enabling studies.